GlassScriptPhysician profile
William Jaremko
NPI 1417941733
$6,987.54
in general payments reported to CMS, 2019-2025
27 companies · $1,760 in 2025
The $1,760 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $288 · 2021: $341 · 2022: $681 · 2023: $1,038 · 2024: $1,084 · 2025: $1,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,441 · Education: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.66 |
| Education | $440.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,168.33 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,041.20 | 2019-2025 | |
| Ucb, INC. | $713.24 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $705.20 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $522.50 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $489.37 | 2019-2025 | |
| Amgen INC. | $342.65 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $319.83 | 2019 | |
| Pfizer INC. | $269.06 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $261.42 | 2019-2025 | Dupixent |
| Incyte Corporation | $178.70 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $149.93 | 2019 | |
| Galderma Laboratories, L.P. | $143.92 | 2019-2025 | Nemluvio |
| Astrazeneca Pharmaceuticals LP | $114.51 | 2025 | Saphnelo |
| Genzyme Corporation | $107.22 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $98.00 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.81 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $73.17 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.01 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $36.34 | 2024 | Zoryve |
| Janssen Scientific Affairs, LLC | $29.23 | 2019 | |
| Organon LLC | $29.16 | 2025 | |
| Prugen, INC. Pharmaceuticals | $17.29 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.06 | 2025 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $14.42 | 2025 | Spinosad, Natroba |
| Helsinn Therapeutics (U.S.), INC. | $12.03 | 2019 | |
| Biofrontera INC. | $8.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jaremko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.